Acquisition of Technology - Additional Information (Detail) (USD $)	1 Months Ended	83 Months Ended			12 Months Ended
	Jun. 30, 2007	Dec. 31, 2013	Jun. 30, 2007 Questcor [Member] Patents [Member]	Jun. 30, 2007 Development Target One, Two and Three [Member] Questcor [Member] Patents [Member]	Dec. 31, 2013 Development Target One [Member] Questcor [Member] Patents [Member]	Dec. 31, 2013 Development Target Two [Member] Questcor [Member] Patents [Member]	Dec. 31, 2013 Development Target Three [Member] Questcor [Member] Patents [Member]	Dec. 31, 2013 Development Target Four [Member] Questcor [Member] Patents [Member]
Business Acquisition, Contingent Consideration [Line Items]
Upfront payment expensed as in-process research and development	$ 650,000	$ 650,000
Milestone payments			52,000,000
Milestone payments, pegged to development targets				$ 5,000,000	$ 500,000	$ 1,500,000	$ 3,000,000	$ 47,000,000
Development targets description					Upon the initiation of the first patient dosing in the Company's planned Phase 3 clinical trial for EVK-001	Upon the U.S. Food and Drug Administration's (the "FDA") acceptance for review of a new drug application for EVK-001	Upon the FDA's approval of EVK-001	Depend on EVK-001's commercial success and will only apply if EVK-001 receives regulatory approval. In addition, the Company will be required to pay to Questcor a low single digit royalty on net sales of EVK-001.
Expected expiration of patent right								2030